Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
You must complete a healthcare providers consultation before purchase
pricing changes will have only a low single digit negative impact on its 2026 global sales growth
In late November 2025, Novo Nordisk reported topline results from the EVOKE and EVOKE+ Phase 3 trials evaluating oral semaglutide in early Alzheimers disease
Anaemia and the risk of progression from non-proliferative diabetic retinopathy to vision threatening diabetic retinopathy
US$ 28.69
US$ 29.44
US$ 21.14
